Table 2.
Subpopulations of monocytes and their activation markers in different time t0, t1 and t2 in placebo and anti-TNF-α treatment.
| Subpopulation | Placebo | Anti-TNF-α Treatment | p Value | ||||
|---|---|---|---|---|---|---|---|
| Timepoint | t0 | t1 | t2 | t0 | t1 | t2 | |
| Monocytes (%) | 19.44 (6.69) |
18.97 (5.70) |
16.80 (5.69) |
21.98 (5.81) |
18.15 (6.23) |
19.96 (5.96) |
p = 0.124 |
| CD45RA MFI | 3188.08 (1223.47) |
3040.25 (914.15) |
3033.00 (822.31) |
2641.50 (1580.84) |
3484.53 (1806.13) |
3654.32 (2189.89) |
p = 0.013 |
| CD11c MFI | 778.92 (140.42) |
901.08 (234.06) |
877.83 (229.42) |
937.24 (407.19) |
972.34 (334.35) |
980.74 (399.46) |
p = 0.832 |
| CD11b MFI | 900.58 (212.85) |
873.17 (166.56) |
834.33 (227.42) |
3310.42 (2993.18) |
4138.79 (4056.15) |
2100.51 (2861.03) |
p = 0.121 |
| HLA-DR MFI | 10984.50 (3181.69) |
12183.08 (4130.38) |
11438.00 (4321.06) |
9481.24 (4661.29) |
12162.82 (6078.35) |
13064.74 (5250.11) |
p = 0.274 |
| CD14dimCD16+ (%) | 6.52 (3.41) |
7.28 (4.29) |
7.14 (4.13) |
4.65 (2.34) |
7.43 (4.53) |
7.98 (3.57) |
p = 0.073 |
| CD45RA MFI | 11065.17 (5181.33) |
10355.00 (5370.98) |
10033.42 (4897.20) |
9254.92 (6000.12) |
10994.37 (5624.30) |
11494.16 (6599.58) |
p = 0.049 |
| CD11c MFI | 2173.75 (318.64) |
2665.25 (573.03) |
2813.00 (868.16) |
2998.82 (1273.40) |
2756.58 (1124.21) |
2690.21 (1206.80) |
p = 0.046 |
| CD11b MFI | 531.92 (106.24) |
556.17 (115.43) |
535.50 (123.92) |
1943.86 (1665.57) |
1931.00 (1835.86) |
1012.83 (1084.80) |
p = 0.028 |
| HLA-DR MFI | 25946.50 (4698.43) |
29249.33 (7221.83) |
27596.17 (6016.55) |
24027.34 (10224.44) |
24758.55 (16111.57) |
26336.08 (17167.62) |
p = 0.771 |
| CD14hiCD16+ | 5.71 (3.54) |
5.03 (2.86) |
3.79 (2.12) |
4.41 (2.40) |
4.97 (3.51) |
4.31 (1.97) |
p = 0.170 |
| CD45RA MFI | 2871.33 (1139.52) |
3070.92 (1566.17) |
2804 (1197.48) |
3046.66 (2779.49) |
3371 (2334.81) |
3456.95 (3063.03) |
p = 0.593 |
| CD11c MFI | 1838.08 (394.12) |
2232.67 (586.69) |
2193.83 (478.66) |
2458.05 (999.10) |
2417 (796.66) |
2435.16 (748.38) |
p = 0.315 |
| CD11b MFI | 1084.00 (266.68) |
1068.25 (209.36) |
1045.50 (265.60) |
4071.86 (3416.93) |
5051.47 (4754.07) |
2548.31 (3371.88) |
p = 0.102 |
| HLA-DR MFI | 49088.17 (11819.53) |
54980.00 (11033.93) |
54020.42 (15785.05) |
45712.00 (19544.37) |
49330.89 (19217.99) |
55932.68 (21573.64) |
p = 0.466 |
| CD14hiCD16− (%) | 86.28 (5.77) |
86.17 (6.87) |
87.13 (5.93) |
89.35 (4.04) |
85.19 (7.47) |
85.54 (4.50) |
p = 0.026 |
| CD45RA MFI | 2002.58 (671.09) |
1935.42 (510.77) |
1853.42 (515.27) |
1862.82 (1281.84) |
1831.71 (968.78) |
1997.26 (1569.28) |
p = 0.297 |
| CD11c MFI | 588.833 (122.13) |
663.25 (144.66) |
644.667 (126.93) |
738.789 (340.83) |
719.447 (254.83) |
723.763 (307.49) |
p = 0.725 |
| CD11b MFI | 909.75 (220.24) |
883.25 (173.51) |
841.42 (231.86) |
3355.67 (3058.44) |
4317.13 (4268.82) |
2210.06 (3167.63) |
p = 0.139 |
| HLA-DR MFI | 7218.33 (2526.62) |
8054.08 (2533.40) |
7921.17 (2929.59) |
6706.42 (3353.68) |
8473.97 (3954.01) |
9368.45 (3641.07) |
p = 0.340 |
Data are shown as mean and standard deviation (SD). Statistical analysis was performed using ANOVA of repeated measures. p Value shown for interaction term (time x group). p Value lower than 0.05 marked as a bold.